Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tilsotolimod · 1 trial · 1 indication
Efficacy measure by objective response rate
Durability or response per RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| IO Naive Subjects MSS CRC | EXPERIMENTAL | 8mg Tilsotolimod by intratumoral injection plus 3mg/kg Nivolumab (every three weeks for four doses followed by 480mg dose every four weeks) and 1mg/kg Ipilimumab every three weeks for four doses intravenous |
| Name | Type | Description |
|---|---|---|
| Tilsotolimod | DRUG | 9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7. |
| Nivolumab | DRUG | Specified dose on specified days. |
| Ipilimumab | DRUG | Specified dose on specified days. |
Main Inclusion Criteria: 1. Subject must be willing and able to sign the informed consent and comply with study protocol. 2. Must be ≥ 18 years of age (males and females). 3. ≥ 1 lesion accessible for i.t. injection and biopsy(ies). 4. Eastern Cooperative Oncology Group (ECOG) performance status of...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Tilsotolimod is an investigational oncology drug being studied for the treatment of solid tumors. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities. The drug is being evaluated in combination with other therapies in patients with solid tumors.
Tilsotolimod is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with solid tumors.
Tilsotolimod is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied in an active clinical trial for the treatment of solid tumors.
Tilsotolimod is being evaluated in a Phase 2 clinical trial with the identifier NCT03865082, titled 'Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)'. This trial is active but not recruiting participants and is being conducted in the United States.
No, Tilsotolimod is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials. The drug is being studied for the treatment of solid tumors, but it has not yet received regulatory approval for any indication.